Allarity Therapeutics Announces Postponement of Annual Stockholders Meeting
Allarity Therapeutics (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company focused on personalized cancer treatments, has announced the postponement of its Annual Meeting of Stockholders. The meeting was originally scheduled for July 26, 2024, at 10:00 AM Eastern Time. The company's Board of Directors made the decision to delay the meeting on July 25, 2024, exercising its authority under the company's bylaws.
Allarity Therapeutics will determine and announce a new date for the Annual Meeting in the future. The company has committed to providing updated information about the new meeting date and, if necessary, a new record date as soon as it becomes available.
Allarity Therapeutics (NASDAQ: ALLR), una società farmaceutica in fase clinica 2 focalizzata su trattamenti personalizzati per il cancro, ha annunciato il rinvio della sua Assemblea Annuale degli Azionisti. L'incontro era inizialmente previsto per il 26 luglio 2024, alle 10:00 AM ora orientale. Il Consiglio di Amministrazione dell'azienda ha preso la decisione di posticipare l'assemblea il 25 luglio 2024, esercitando la propria autorità secondo lo statuto aziendale.
Allarity Therapeutics stabilirà e annuncerà una nuova data per l'Assemblea Annuale in futuro. L'azienda si è impegnata a fornire informazioni aggiornate riguardo alla nuova data dell'incontro e, se necessario, una nuova data di registrazione non appena saranno disponibili.
Allarity Therapeutics (NASDAQ: ALLR), una compañía farmacéutica en fase clínica 2 enfocada en tratamientos personalizados para el cáncer, ha anunciado el aplazamiento de su Junta Anual de Accionistas. La reunión estaba originalmente programada para el 26 de julio de 2024, a las 10:00 AM hora del este. La Junta Directiva de la compañía tomó la decisión de retrasar la reunión el 25 de julio de 2024, ejerciendo su autoridad bajo los estatutos de la compañía.
Allarity Therapeutics determinará y anunciará una nueva fecha para la Junta Anual en el futuro. La compañía se ha comprometido a proporcionar información actualizada sobre la nueva fecha de la reunión y, si es necesario, una nueva fecha de registro tan pronto como esté disponible.
Allarity Therapeutics (NASDAQ: ALLR), 개인 맞춤형 암 치료에 중점을 둔 2상 임상 단계 제약 회사는 주주 연례 총회 연기를 발표했습니다. 총회는 원래 2024년 7월 26일 오전 10:00 동부 시간으로 예정되어 있었습니다. 회사의 이사회는 회사의 정관에 따라 2024년 7월 25일 총회 연기 결정을 내렸습니다.
Allarity Therapeutics는 향후 연례 총회의 새로운 날짜를 결정하고 발표할 것입니다. 회사는 회의 날짜 변경 사항과 필요한 경우 새로운 기준일에 대한 업데이트 정보를 가능한 한 빨리 제공하겠다고 약속했습니다.
Allarity Therapeutics (NASDAQ: ALLR), une société pharmaceutique en phase clinique 2 spécialisée dans les traitements personnalisés du cancer, a annoncé le report de son Assemblée Générale Annuelle des Actionnaires. La réunion était initialement prévue pour le 26 juillet 2024 à 10h00, heure de l'Est. Le Conseil d'Administration de l'entreprise a décidé de reporter la réunion le 25 juillet 2024, exerçant son autorité en vertu des statuts de l'entreprise.
Allarity Therapeutics déterminera et annoncera une nouvelle date pour l'Assemblée Annuelle à l'avenir. L'entreprise s'est engagée à fournir des informations mises à jour concernant la nouvelle date de la réunion et, si nécessaire, une nouvelle date de référence dès qu'elle sera disponible.
Allarity Therapeutics (NASDAQ: ALLR), ein biopharmazeutisches Unternehmen in der klinischen Phase 2, das sich auf personalisierte Krebstherapien spezialisiert hat, hat die Verschiebung seiner Hauptversammlung der Aktionäre bekannt gegeben. Die Versammlung war ursprünglich für den 26. Juli 2024 um 10:00 Uhr Ostküstenzeit geplant. Der Vorstand des Unternehmens traf die Entscheidung, die Versammlung am 25. Juli 2024 zu verschieben, und übt dabei seine Befugnisse gemäß der Satzung des Unternehmens aus.
Allarity Therapeutics wird zu gegebener Zeit ein neues Datum für die Hauptversammlung festlegen und bekannt geben. Das Unternehmen hat sich verpflichtet, aktualisierte Informationen über das neue Versammlungsdatum und gegebenenfalls ein neues Stichtagsdatum zur Verfügung zu stellen, sobald diese verfügbar sind.
- None.
- None.
Boston (July 26, 2024)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, announced that its Board of Directors has decided to postpone the Annual Meeting of Stockholders, which was originally scheduled for 10:00 AM Eastern Time today, July 26, 2024.
On July 25, 2024, the Board, exercising its authority under the Company’s bylaws, opted to delay the meeting to a future date, which will be determined and announced in due course.
The Company will provide updated information regarding the new date for the Annual Meeting and, if necessary, a new record date, as soon as it becomes available.
About Allarity Therapeutics
Allarity Therapeutics, Inc. (NASDAQ: ALLR) is a clinical-stage biopharmaceutical company dedicated to developing personalized cancer treatments. The Company is focused on development of stenoparib, a novel PARP/Tankyrase inhibitor for advanced ovarian cancer patients, using its DRP® companion diagnostic for patient selection in the ongoing phase 2 clinical trial, NCT03878849. Allarity is headquartered in the U.S., with a research facility in Denmark, and is committed to addressing significant unmet medical needs in cancer treatment. For more information, visit www.allarity.com.
Follow Allarity on Social Media
LinkedIn: https://www.linkedin.com/company/allaritytx/
X: https://twitter.com/allaritytx
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements provide the Company’s current expectations or forecasts of future events. The words “anticipates,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predicts,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, statements regarding the Company's plans to announce a new date for the postponed Annual Meeting of Stockholders and the timing of related updates. Any forward-looking statements in this press release are based on management’s current expectations of future events and are subject to multiple risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the potential impact of the postponement of the Annual Meeting on stockholder engagement and decision-making, and the Company’s ability to provide timely updates on the rescheduled meeting and any new record date. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in our Form S-1 registration statement filed on April 17, 2024, and our Form 10-K annual report on file with the Securities and Exchange Commission (the “SEC”), available at the SEC’s website at www.sec.gov, and as well as discussions of potential risks, uncertainties and other important factors in the Company’s subsequent filings with the SEC. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information unless required by law.
###
Company Contact:
investorrelations@allarity.com
Media Contact:
Thomas Pedersen
Carrotize PR & Communications
+45 6062 9390
tsp@carrotize.com
Attachment
FAQ
Why did Allarity Therapeutics (ALLR) postpone its Annual Stockholders Meeting in July 2024?
When will Allarity Therapeutics (ALLR) announce the new date for its postponed Annual Stockholders Meeting?
What is Allarity Therapeutics' (ALLR) current stage of development as of July 2024?
Will Allarity Therapeutics (ALLR) set a new record date for the postponed Annual Stockholders Meeting?
